Mesenchymal Stem Cell Infusion in Haploidentical Hematopoietic Stem Cell Transplantation in Patients With Hematological Malignancies

PHASE3CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

July 31, 2017

Study Completion Date

October 31, 2017

Conditions
Hematopoietic Stem Cell Transplantation
Interventions
BIOLOGICAL

mesenchymal stem cells

After preferred conditioning regimen for the patient, cyclophosphamide 50 mg/kg/day will be administered at +3 and +4 post transplant day. At +6 post transplant day, 2-8x10\^8 cell/kg mesenchymal stem cells will be infused.

DRUG

cyclophosphamide administration

After preferred conditioning regimen for the patient, cyclophosphamide 50 mg/kg/day will be administered at +3 and +4 post transplant day.

Trial Locations (1)

Unknown

Ankara University School of Medicine Department of Hematology, Ankara

All Listed Sponsors
collaborator

The Scientific and Technological Research Council of Turkey

OTHER

lead

Ankara University

OTHER

NCT03106662 - Mesenchymal Stem Cell Infusion in Haploidentical Hematopoietic Stem Cell Transplantation in Patients With Hematological Malignancies | Biotech Hunter | Biotech Hunter